Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
Public ClinicalTrials.gov record NCT04396106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19
Study identification
- NCT ID
- NCT04396106
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- AT-527 Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2020
- Primary completion
- Jan 9, 2022
- Completion
- Feb 27, 2022
- Last update posted
- Mar 8, 2023
2020 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Atea Study Site | Scottsdale | Arizona | 85258 | — |
| Atea Study Site | Davis | California | 95817 | — |
| Atea Study Site | Los Angeles | California | 90017 | — |
| Atea Study Site | Washington D.C. | District of Columbia | 20037 | — |
| Atea Study Site | Orlando | Florida | 32804 | — |
| Atea Study Site | Atlanta | Georgia | 30303 | — |
| Atea Study Site | Chicago | Illinois | 60611 | — |
| Atea Study Site | Chicago | Illinois | 60612 | — |
| Atea Study Site | Boston | Massachusetts | 02115 | — |
| Atea Study Site | Butte | Montana | 59701 | — |
| Atea Study Site | Charlotte | North Carolina | 28204 | — |
| Atea Study Site | Cincinnati | Ohio | 45219 | — |
| Atea Study Site | Columbus | Ohio | 43203 | — |
| Atea Study Site | Charleston | South Carolina | 29425 | — |
| Atea Study Site | Columbia | South Carolina | 29203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04396106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04396106 live on ClinicalTrials.gov.